<VariationArchive VariationID="167146" VariationName="NM_000404.4(GLB1):c.1077del (p.Val360fs)" VariationType="Deletion" Accession="VCV000167146" Version="16" RecordType="classified" NumberOfSubmissions="7" NumberOfSubmitters="7" DateLastUpdated="2024-04-06" DateCreated="2015-06-28" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="177750" VariationID="167146">
      <GeneList>
        <Gene Symbol="GLB1" FullName="galactosidase beta 1" GeneID="2720" HGNC_ID="HGNC:4298" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>3p22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="32961108" stop="33097146" display_start="32961108" display_stop="33097146" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33038099" stop="33138693" display_start="33038099" display_stop="33138693" Strand="-" />
          </Location>
          <OMIM>611458</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000404.4(GLB1):c.1077del (p.Val360fs)</Name>
      <CanonicalSPDI>NC_000003.12:33024316:TTTTT:TTTT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="33024317" stop="33024317" display_start="33024317" display_stop="33024317" variantLength="1" positionVCF="33024316" referenceAlleleVCF="CT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33065809" stop="33065809" display_start="33065809" display_stop="33065809" variantLength="1" positionVCF="33065808" referenceAlleleVCF="CT" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>V330fs</ProteinChange>
      <ProteinChange>V408fs</ProteinChange>
      <ProteinChange>V360fs</ProteinChange>
      <ProteinChange>V229fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.33065813del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.33065813del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.33024321del" Assembly="GRCh38">
            <Expression>NC_000003.12:g.33024321del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009005.1" sequenceAccession="NG_009005" sequenceVersion="1" change="g.77886del">
            <Expression>NG_009005.1:g.77886del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.4" sequenceAccession="NM_000404" sequenceVersion="4" change="c.1077del" MANESelect="true">
            <Expression>NM_000404.4:c.1077del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000395.3" sequenceAccession="NP_000395" sequenceVersion="3" change="p.Val360fs">
            <Expression>NP_000395.3:p.Val360fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079811.3" sequenceAccession="NM_001079811" sequenceVersion="3" change="c.987del">
            <Expression>NM_001079811.3:c.987del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073279.2" sequenceAccession="NP_001073279" sequenceVersion="2" change="p.Val330fs">
            <Expression>NP_001073279.2:p.Val330fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001135602.3" sequenceAccession="NM_001135602" sequenceVersion="3" change="c.684del">
            <Expression>NM_001135602.3:c.684del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001129074.2" sequenceAccession="NP_001129074" sequenceVersion="2" change="p.Val229fs">
            <Expression>NP_001129074.2:p.Val229fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001317040.2" sequenceAccession="NM_001317040" sequenceVersion="2" change="c.1221del">
            <Expression>NM_001317040.2:c.1221del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001303969.2" sequenceAccession="NP_001303969" sequenceVersion="2" change="p.Val408fs">
            <Expression>NP_001303969.2:p.Val408fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001393580.1" sequenceAccession="NM_001393580" sequenceVersion="1" change="c.1077del">
            <Expression>NM_001393580.1:c.1077del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001380509.1" sequenceAccession="NP_001380509" sequenceVersion="1" change="p.Val360fs">
            <Expression>NP_001380509.1:p.Val360fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.4" sequenceAccession="NM_000404" sequenceVersion="4" change="c.1077delA" MANESelect="true">
            <Expression>NM_000404.4:c.1077delA</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.3" sequenceAccession="NM_000404" sequenceVersion="3" change="c.1077delA">
            <Expression>NM_000404.3:c.1077delA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="727503952" DB="dbSNP" />
        <XRef ID="CA200785" DB="ClinGen" />
      </XRefList>
      <FunctionalConsequence Value="Unknown function" />
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000404.4(GLB1):c.1077del (p.Val360fs) AND not provided" Accession="RCV000173999" Version="5">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2013-12-19" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.1077del (p.Val360fs) AND multiple conditions" Accession="RCV001035980" Version="4">
        <ClassifiedConditionList TraitSetID="10013">
          <ClassifiedCondition DB="MedGen" ID="C0085131">GM1 gangliosidosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0086652">Mucopolysaccharidosis, MPS-IV-B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-03-27" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.1077del (p.Val360fs) AND Mucopolysaccharidosis, MPS-IV-B" Accession="RCV001192990" Version="2">
        <ClassifiedConditionList TraitSetID="247">
          <ClassifiedCondition DB="MedGen" ID="C0086652">Mucopolysaccharidosis, MPS-IV-B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-02-17" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.1077del (p.Val360fs) AND Infantile GM1 gangliosidosis" Accession="RCV002291499" Version="3">
        <ClassifiedConditionList TraitSetID="244">
          <ClassifiedCondition DB="MedGen" ID="C0268271">Infantile GM1 gangliosidosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-09-30" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.1077del (p.Val360fs) AND GM1 gangliosidosis" Accession="RCV002470776" Version="1">
        <ClassifiedConditionList TraitSetID="11702">
          <ClassifiedCondition DB="MedGen" ID="C0085131">GM1 gangliosidosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-05-21" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-03-27" NumberOfSubmissions="7" NumberOfSubmitters="7" DateCreated="2015-06-28" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">18524657</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20175788</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25936995</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30408610</ID>
        </Citation>
        <Citation Type="general">
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=GLB1</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="11702" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7352" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis</ElementValue>
                <XRef ID="MONDO:0018149" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Beta galactosidase 1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB 1 deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10891" />
                <XRef ID="10891" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="C0085131" DB="MedGen" />
              <XRef ID="MONDO:0018149" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="10013" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2965" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis Type IVB</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-IV-B</ElementValue>
                <XRef ID="Morquio+syndrome+B/4877" DB="Genetic Alliance" />
                <XRef ID="238044004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS IVB</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Morquio syndrome B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 4B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IVB (Morquio)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IV B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type 4B</ElementValue>
                <XRef ID="MONDO:0009660" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS4B</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3786" />
                <XRef ID="3786" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="309310" DB="Orphanet" />
              <XRef ID="582" DB="Orphanet" />
              <XRef ID="C0086652" DB="MedGen" />
              <XRef ID="MONDO:0009660" DB="MONDO" />
              <XRef Type="MIM" ID="253010" DB="OMIM" />
            </Trait>
            <Trait ID="7352" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis</ElementValue>
                <XRef ID="MONDO:0018149" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Beta galactosidase 1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB 1 deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10891" />
                <XRef ID="10891" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="C0085131" DB="MedGen" />
              <XRef ID="MONDO:0018149" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="244" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5204" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Infantile GM1 gangliosidosis</ElementValue>
                <XRef ID="238026007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-gangliosidosis, type I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, generalized GM1, infantile form</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1 gangliosidosis type 1</ElementValue>
                <XRef ID="MONDO:0009260" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 1</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6479" />
                <XRef ID="6479" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="79255" DB="Orphanet" />
              <XRef ID="C0268271" DB="MedGen" />
              <XRef ID="MONDO:0009260" DB="MONDO" />
              <XRef Type="MIM" ID="230500" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="247" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2965" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis Type IVB</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-IV-B</ElementValue>
                <XRef ID="Morquio+syndrome+B/4877" DB="Genetic Alliance" />
                <XRef ID="238044004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS IVB</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Morquio syndrome B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 4B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IVB (Morquio)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IV B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type 4B</ElementValue>
                <XRef ID="MONDO:0009660" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS4B</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3786" />
                <XRef ID="3786" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="309310" DB="Orphanet" />
              <XRef ID="582" DB="Orphanet" />
              <XRef ID="C0086652" DB="MedGen" />
              <XRef ID="MONDO:0009660" DB="MONDO" />
              <XRef Type="MIM" ID="253010" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="413530" SubmissionDate="2017-06-30" DateLastUpdated="2015-06-28" DateCreated="2015-06-28">
        <ClinVarSubmissionID localKey="2470_000000" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000225218" DateUpdated="2015-06-28" DateCreated="2015-06-28" Type="SCV" Version="5" SubmitterName="Eurofins Ntd Llc (ga)" OrgID="500060" OrganizationCategory="laboratory" OrgAbbreviation="EGL" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000225221" DateChanged="2019-08-06" Version="4">
            <Comment Type="MergeComment">SCV000225221 was merged into SCV000225218 to remove duplication.</Comment>
          </Replaced>
          <Replaced Accession="SCV000225220" DateChanged="2019-08-06" Version="4">
            <Comment Type="MergeComment">SCV000225220 was merged into SCV000225218 to remove duplication.</Comment>
          </Replaced>
          <Replaced Accession="SCV000225219" DateChanged="2019-08-06" Version="4">
            <Comment Type="MergeComment">SCV000225219 was merged into SCV000225218 to remove duplication.</Comment>
          </Replaced>
          <Replaced Accession="SCV000202808" DateChanged="2018-02-14" Version="2" />
        </ReplacedList>
        <Classification DateLastEvaluated="2013-12-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">EGL Classification Definitions</Attribute>
          <Citation>
            <URL>http://www.egl-eurofins.com/emvclass/EGLClassificationDefinitions.php</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <Gender>mixed</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="9" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Homozygote" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="8" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="3" alternateAllele="-" referenceAllele="T" start="33065809" stop="33065809" variantLength="1" />
            <GeneLocation>NM_000404.2:Ex11</GeneLocation>
          </Location>
          <XRefList>
            <XRef DB="HGMD" ID="CD105073" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <Citation>
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=GLB1</URL>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>EGL005</SubmissionName>
          <SubmissionName>PILOT_TEST_03</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5026056" SubmissionDate="2022-09-08" DateLastUpdated="2022-09-17" DateCreated="2022-09-17">
        <ClinVarSubmissionID localKey="NM_000404.4:c.1077delA|OMIM:253010" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002570296" DateUpdated="2022-09-17" DateCreated="2022-09-17" Type="SCV" Version="1" SubmitterName="Johns Hopkins Genomics, Johns Hopkins University" OrgID="506823" OrganizationCategory="laboratory" OrgAbbreviation="JHG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20175788</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25936995</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.4:c.1077delA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="253010" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12035625</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5049612" SubmissionDate="2022-10-13" DateLastUpdated="2022-10-22" DateCreated="2022-10-22">
        <ClinVarSubmissionID localKey="SUB12148419" submittedAssembly="GRCh38" title="SUB12148419" />
        <ClinVarAccession Accession="SCV002583284" DateUpdated="2022-10-22" DateCreated="2022-10-22" Type="SCV" Version="1" SubmitterName="Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics" OrgID="505565" OrganizationCategory="other" OrgAbbreviation="FRIGE - IHG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-09-30">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The variant has shown a homozygous status for c.1221del (p.Val408TyrfsTer23) in exon 12 of the GLB1 gene. This variant is not reported in the 1000 genomes and gnomAD databases. The in-silico prediction of the variant is disease causing mutation Taster2.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <NamePlatform>Illumina sequencing platform</NamePlatform>
              <TypePlatform>Next-generation sequencing</TypePlatform>
              <Description>DNA was used to perform targeted gene capture using a custom capture kit. Libraries were sequenced to mean &gt;80-100X coverage on Illumina sequencing platform. Sequence obtained were aligned to human references genome using BWA program and analyzed using Picard and GATK-Lite toolkit to identify variants in the targeted genes relevant to clinical indication.</Description>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Homozygote" integerValue="1" />
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001433" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001252" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0002751" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0010729" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1">
              <Name>galactosidase beta 1</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_001317040.1:exon 12</GeneLocation>
          </Location>
          <FunctionalConsequence Value="Unknown function" />
          <AttributeSet>
            <Attribute Type="HGVS">NM_001317040.1:c.1221del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230500" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12148419</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7574580" SubmissionDate="2023-10-19" DateLastUpdated="2023-10-28" DateCreated="2023-10-28">
        <ClinVarSubmissionID localKey="20400118291_1" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004047844" DateUpdated="2023-10-28" DateCreated="2023-10-28" Type="SCV" Version="1" SubmitterName="Neuberg Centre For Genomic Medicine, NCGM" OrgID="508108" OrganizationCategory="laboratory" OrgAbbreviation="NCGM" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The c.1077del (p.Val360TyrfsTer23) frameshift variant in GLB1 gene has been observed in several individuals affected with GM1 gangliosidosis (Hofer et al., 2010; Bidchol et al., 2015). This variant is reported with the allele frequency (0.0008%) in the gnomAD and novel in 1000 genome database. This variant has been reported to the ClinVar database as Pathogenic. This variant causes a frameshift starting with codon Valine 360, changes this amino acid to Tyrosine residue, and creates a premature Stop codon at position 23 of the new reading frame, denoted p.Val360TyrfsTer23. Loss-of-function variants in GLB1 are known to be pathogenic (Brunetti-Pierri and Scaglia, 2008). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0002376" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0002071" />
              </Trait>
              <Comment>Clinical symptoms and progression: neuroregression, extrapyramidal syndrome, tics and tremors. Investigations: MRI brain- basal ganglia hyperintensity Clinical suspicion: Late onset leigh syndrome; Pantothenate kinase-associated neurodegeneration (PKAN); neuronal brain iron accumulation syndrome,</Comment>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.4:c.1077del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230500" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13901154</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2364459" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="4841629|MedGen:C0086652;C0085131" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001199320" DateUpdated="2024-02-28" DateCreated="2020-04-15" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-03-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20175788</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25936995</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18524657</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 167146). This variant is also known as p.K359Kfs*23. This premature translational stop signal has been observed in individuals with GM1 gangliosidosis (PMID: 20175788, 25936995). This variant is present in population databases (rs727503952, gnomAD 0.007%). This sequence change creates a premature translational stop signal (p.Val360Tyrfs*23) in the GLB1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GLB1 are known to be pathogenic (PMID: 18524657).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.33065809del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0086652" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0085131" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2669815" SubmissionDate="2020-03-06" DateLastUpdated="2020-06-22" DateCreated="2020-06-22">
        <ClinVarSubmissionID localKey="NM_000404.2:c.1077del|MedGen:C0086652" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001361488" DateUpdated="2020-06-22" DateCreated="2020-06-22" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-01-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">25936995</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20175788</ID>
          </Citation>
          <Comment>Variant summary: GLB1 c.1077delA (p.Val360TyrfsX23) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by other laboratories (eg. c.1174_1175delCT/p.Leu392Valfs, c.1188dupG/p.Pro397Alafs). The variant allele was found at a frequency of 8.2e-06 in 243488 control chromosomes. c.1077delA has been reported in the literature in multiple individuals affected with Mucopolysaccharidosis Type IVB (Morquio Syndrome B, Hofer_2010, Bidchol_2015). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.2:c.1077del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-IV-B</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0086652" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6913290</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5413887" SubmissionDate="2022-12-21" DateLastUpdated="2022-12-24" DateCreated="2022-12-24">
        <ClinVarSubmissionID localKey="vcgs/unit_1/hg38_NM_000404_3_GLB1_c_1077delA" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002767566" DateUpdated="2022-12-24" DateCreated="2022-12-24" Type="SCV" Version="1" SubmitterName="Victorian Clinical Genetics Services, Murdoch Childrens Research Institute" OrgID="500104" OrganizationCategory="laboratory" OrgAbbreviation="VCGS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-05-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20175788</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25936995</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30408610</ID>
          </Citation>
          <Comment>A heterozygous frameshift deletion variant was identified, NM_000404.3(GLB1):c.1077del in exon 11 of 16 of the GLB1 gene. This deletion is predicted to cause a frameshift starting at position 360, NP_000395.2(GLB1):p.(Val360Tyrfs*23), resulting in a loss of normal protein function through nonsense-mediated decay (NMD). The variant is present in the gnomAD population database at a frequency of 0.0008% (2 heterozygotes; 0 homozygotes), observed within the South Asian population only. The variant has previously been reported as pathogenic in patients with GM1-gangliosidosis, and has been observed in cis with a missense variant (NM_000404.3(GLB1):c.1071T&gt;G; NP_000395.2(GLB1):p.(Phe357Leu)) (ClinVar, Hofer, D. et al. (2012), Bidchol, A. et al. (2015), Uttarilli, A. et al. (2019)). Other variants predicted to cause NMD have also been reported as pathogenic in individuals with this condition (ClinVar). Based on information available at the time of curation, this variant has been classified as PATHOGENIC.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_2558</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.3:c.1077delA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0018149" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_38</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7574580" TraitType="Finding" MappingType="XRef" MappingValue="HP:0002376" MappingRef="HP">
        <MedGen CUI="C1836830" Name="Developmental regression" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7574580" TraitType="Disease" MappingType="XRef" MappingValue="230500" MappingRef="OMIM">
        <MedGen CUI="C0268271" Name="Infantile GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2364459" TraitType="Disease" MappingType="XRef" MappingValue="C0085131" MappingRef="MedGen">
        <MedGen CUI="C0085131" Name="GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5049612" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001252" MappingRef="HP">
        <MedGen CUI="C0026827" Name="Hypotonia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7574580" TraitType="Finding" MappingType="XRef" MappingValue="HP:0002071" MappingRef="HP">
        <MedGen CUI="C0234133" Name="Abnormality of extrapyramidal motor function" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5049612" TraitType="Finding" MappingType="XRef" MappingValue="HP:0002751" MappingRef="HP">
        <MedGen CUI="C0575158" Name="Kyphoscoliosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="413530" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5413887" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0018149" MappingRef="MONDO">
        <MedGen CUI="C0085131" Name="GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2364459" TraitType="Disease" MappingType="XRef" MappingValue="C0086652" MappingRef="MedGen">
        <MedGen CUI="C0086652" Name="Mucopolysaccharidosis, MPS-IV-B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5049612" TraitType="Finding" MappingType="XRef" MappingValue="HP:0010729" MappingRef="HP">
        <MedGen CUI="C2216370" Name="Cherry red spot of the macula" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5026056" TraitType="Disease" MappingType="XRef" MappingValue="253010" MappingRef="OMIM">
        <MedGen CUI="C0086652" Name="Mucopolysaccharidosis, MPS-IV-B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5049612" TraitType="Disease" MappingType="XRef" MappingValue="230500" MappingRef="OMIM">
        <MedGen CUI="C0268271" Name="Infantile GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2669815" TraitType="Disease" MappingType="Name" MappingValue="Mucopolysaccharidosis, MPS-IV-B" MappingRef="Preferred">
        <MedGen CUI="C0086652" Name="Mucopolysaccharidosis, MPS-IV-B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5049612" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001433" MappingRef="HP">
        <MedGen CUI="C0019214" Name="Hepatosplenomegaly" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

